美国Osiris Therapeutics
美国Osiris关注与间质干细胞地位（MSC）的技术，职前临床，在疾病的动物模型，并在诊所也。近年来，该公司赞助了一些临床试验，以评估产品的安全性和有效性。

Osiris Therapeutics, Inc. has focused on the advancement of mesenchymal stem cell (MSC) technologies both pre-clinically, in animal models of disease, and also in the clinic. In recent years, the Company has sponsored a number of clinical trials to evaluate product safety and efficacy.

The primary thrust of the near-term business strategy revolves around the clinical development of product candidates in a variety of indications. The inflammatory program focuses on providing support for bone marrow transplantation after chemotherapy or radiation therapy. The goal is to treat graft versus host disease (GvHD), a life-threatening complication following the receipt of bone marrow from another individual. The cardiac program focuses on MSCs to improve heart function following myocardial infarction (MI) and to prevent progression to congestive heart failure (CHF). Osiris Therapeutics has entered into a strategic alliance with Boston Scientific Corporation for this product area. In orthopedic applications, MSCs may be useful in regenerating meniscal tissue in the weeks following surgery for knee injuries, thereby preventing arthritis.

The lead investor of the company is Friedli Corporate Finance. Friedli Corporate Finance was founded by Peter Friedli in 1986 and is one of the leading Swiss venture capital firms. Since its inception, Friedli Corporate Finance has invested in over 170 biotechnology and technology companies, primarily based in the US. Friedli Corporate Finance manages several investment companies for pension funds, banks and large corporations in Switzerland. Peter Friedli is also a Director of Osiris, Inc. and the manager of New Venturetec, a public investment company listed on the Swiss exchange.